MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX OTC: MPSYY) today increased its financial guidance for the current year. For the full-year 2013, MorphoSys now expects an EBIT of EUR 7 million to EUR 10 million (up from previously EUR 2 million to EUR 6 million) and revenues at the upper end of the previously communicated guidance range of EUR 74 million to EUR 78 million. The change of the EBIT range is mainly driven by the positive revenue development and lower than originally anticipated costs for the development of the cancer program MOR202 under the co-development and cost-sharing agreement with Celgene. "The successful development of our proprietary portfolio and our partnered programs is reflected in the strong financial performance this year. We believe MorphoSys is well positioned and well-funded to broaden and advance its proprietary development activities and to continue to build significant value," stated Jens Holstein, Chief Financial Officer of MorphoSys AG.
Help employers find you! Check out all the jobs and post your resume.
